Opus Genetics (IRD) Times Interest Earned (2011 - 2026)

Opus Genetics' (IRD) quarterly Times Interest Earned came in at -$143.64 in Q1 2026, up 59.87% on a QoQ basis from -$357.91 in Q4 2025.

Opus Genetics (IRD) Times Interest Earned (2011 - 2026) Analysis & Trends

Opus Genetics (IRD) has 14 years of Times Interest Earned data on file, last reported at -$143.64 in Q1 2026.

On a quarterly basis, Times Interest Earned changed N/A year-over-year to -$143.64 in Q1 2026; TTM through Mar 2026 was -$185.49, a N/A change from a year earlier, with the FY2025 full-year figure at -$0.97, changed N/A from the prior year.
Times Interest Earned for Q1 2026 stood at -$143.64, up from -$357.91 in the prior quarter.
Over the last five years, Times Interest Earned for IRD reached as high as -$83.11 in Q3 2025 and fell as low as -$1301.6 in Q1 2022.
Historically, Times Interest Earned has averaged -$624.15 across 3 years, with a median of -$357.91 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	658.42
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-157.58
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	7.60
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.71
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	22.72
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-0.38
10	Opus Genetics	263.72 Mn	203.72 Mn	-	-143.64

Download Data